Clinical Trials on Bone Marrow Failure Syndromes in Belgium

Total 307 results

Novartis Pharmaceuticals

Terminated

A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. (EXPHAR)

Myelodysplastic Syndrome

Belgium
University Hospital Freiburg

Completed

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Pearson Marrow-pancreas Syndrome | Shwachman-diamond Syndrome

Spain, Germany, Switzerland, Austria, Netherlands, Italy, Czech Republic, Belgium, Denmark, Ireland
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Novartis Pharmaceuticals

Terminated

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
European Organisation for Research and Treatment...

Unknown

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Anemia

Belgium, Switzerland, Czech Republic, Portugal, Austria, Netherlands, Slovakia
European Working Group of MDS in Childhood

Unknown

Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

Germany, Austria, Switzerland, Czech Republic, Netherlands, Denmark, Belgium, Italy, Poland
European Organisation for Research and Treatment...

Completed

Infliximab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Belgium, Netherlands, Czech Republic, Italy, Germany
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
Janssen Research & Development, LLC

Terminated

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

France, Belgium, Portugal
University Hospital, Antwerp

Unknown

Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL (Be-QUALMS)

Myelodysplastic Syndromes

Belgium
Celyad Oncology SA

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Belgium, United States
European Organisation for Research and Treatment...

Completed

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

Belgium, Switzerland, Netherlands, Germany
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
Bristol-Myers Squibb

Recruiting

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (MAXILUS)

Myelodysplastic Syndromes

Spain, United States, France, Italy, Belgium, Germany, Poland, Czechia, Puerto Rico
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
University Hospital, Ghent

Completed

Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)

Bone Metastases

Belgium
Syros Pharmaceuticals

Recruiting

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States, Spain, Belgium, Israel, France, United Kingdom, Austria, Czechia, Italy, Poland, Canada, Hungary, Germany
Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
Novartis Pharmaceuticals

Completed

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Myelofibrosis | Sickle Cell Disease | Thalassemia | Diamond Blackfan Anemia

United States, Netherlands, Taiwan, Thailand, Italy, Germany, Spain, Canada, Belgium, Greece, Turkey, United Kingdom
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
Amgen

Completed

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

MDS

Germany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey
University Hospital, Ghent

Unknown

Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases

Bone Metastases

Belgium
AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Hungary
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia (AML-14A)

Myelodysplastic Syndromes | Leukemia

Belgium, Croatia, France, Italy, Netherlands
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
VectivBio AG

Completed

Metabolic Balance Study of Apraglutide in Patients With SBS-IF and Colon-in-Continuity (STARSnutrition)

Short Bowel Syndrome

Belgium, France
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

United Kingdom, Germany, Belgium
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes (PROMYS)

Myelodysplastic Syndromes | Adult

Belgium, United States, Austria, United Kingdom, Italy, Taiwan, Brazil, China, Croatia, Czechia, France, Germany
Celgene Corporation
ICON Clinical Research

Completed

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Myelodysplastic Syndromes

Germany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
Radboud University Medical Center
Universitaire Ziekenhuizen KU Leuven

Completed

Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections (PIRAÑA)

Acute Graft Versus Host Disease | Allogeneic Stem Cell Transplant | Acute Myeloid Leucaemia | Myelo Dysplastic Syndrome

Belgium, Netherlands
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
European Organisation for Research and Treatment...

Completed

Empirical Versus Preemptive Antifungal Therapy

Myelodysplastic Syndromes | Leukemia | Fungal Infection

Belgium, Netherlands, Germany, France, Czechia, Slovakia
Tools4Patient

Completed

A Study to Collect Data About Analgesia in Patients With Bone Metastasis

Bone Metastasis

Belgium, France
Celyad Oncology SA

Unknown

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)

Acute Myeloid Leukemia/Myelodysplastic Syndrome | Multiple Myeloma (MM)

United States, Belgium
European Organisation for Research and Treatment...

Unknown

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Myelodysplastic Syndromes | Leukemia

Switzerland, Netherlands, France, Belgium, Germany, Sweden, Croatia, Czech Republic, Italy
Radboud University Medical Center

Completed

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease (MATADOR)

Allogeneic Stem Cell Transplant | Acute Myeloid Leucaemia | Myelo Dysplastic Syndrome | Acute Graft Versus Host Disease Grade II-IV

Netherlands, Belgium
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
Kiadis Pharma

Completed

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Canada, Netherlands, Germany, Belgium, United Kingdom
Cliniques universitaires Saint-Luc- Université...

Terminated

Early Physical Therapy in Patients With Sepsis (EARTH-ICU)

Multiple Organ Dysfunction Syndrome | SEPTIC SHOCK | SEPSIS SYNDROME

Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland
CTI BioPharma; Dutch Cancer Society

Active, not recruiting

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF)

Myelofibrosis

Netherlands, Belgium
Astex Pharmaceuticals, Inc.

Completed

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United States, Spain, Korea, Republic of, France, Denmark, Canada, Germany, Italy, Czechia, United Kingdom, Poland, Japan, Sweden, Belgium

Clinical Trials on Bone Marrow Failure Syndromes in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations